Bahija Jallal, President, MedImmune and Executive Vice President, AstraZeneca, is responsible for biologics research, development and clinical activities.

Bahija joined MedImmune as Vice-President, Translational Sciences in 2006. She has guided the MedImmune R&D organisation through unprecedented expansion of its pipeline from 40 drugs to more than 120. Biologics now makes up 50% of AstraZeneca’s pipeline. Bahija has authored more than 70 peer-reviewed publications and holds more than 15 patents. She is a member of the American Association of Cancer Research, the American Association of Science, the Pharmacogenomics Working Group and is a member of the Board of Directors of the Association of Women in Science.

Bahija also serves on the Board of Trustees of the Johns Hopkins University in Baltimore, Maryland. Bahija received a master’s degree in Biology from the Universite de Paris VII in France, and her doctorate in Physiology from the University of Pierre & Marie Curie in Paris. She conducted her postdoctoral research at the Max-Planck Institute of Biochemistry in Martinsried, Germany.

Science is my passion and the patient is my purpose. I am truly humbled to be working in such a noble profession. I have the best job in the world. Every day I have the opportunity to come to work to try to make a real difference in the quality of life for people with unmet medical needs.

Bahija Jallal


Executive Vice-President of AstraZeneca and Head of MedImmune


At SUGEN, INC., a subsidiary of Pfizer (Pharmacia), Bahija led a senior R&D team to regulatory approval of a receptor protein-tyrosine kinase inhibitor for the treatment of gastrointestinal stromal tumor, advanced renal cell cancer and advanced pancreatic neuroendocrine tumor


2015 East-West CEO Conference. R&D Trends: What’s Changed in the Pharma Pipeline?


2015 Biotech Showcase, San Francisco: Investing in the Immuno-Oncology Revolution

  Featured publications

MiR-125a targets effector programs

MiR-125a targets effector programs to stabilize Treg-mediated immune homeostasis. Pan W, Zhu S2 Dai D, Liu Z, Li D, Li B, Gagliani N, Zheng Y, Tang Y, Weirauch MT, Chen X, Zhu W, Wang Y, Chen B, Qian Y, Chen Y, Fang J, Herbst R, Richman L, Jallal B, Harley JB, Flavell RA, Yao Y, Shen N. Nat Commun. 2015 May 12;6:7096

Type I IFN as a target

Type I IFN as a target in diseases of systemic lupus erythematosus, myositis, multiple sclerosis and rheumatoid arthritis using transcript profiling of peripheral blood. Brandon Higgs, Zheng Liu, Wendy White, Laura Richman, Bahija Jallal, and Yihong Yao. European Musculoskeletal Review. 2012, Vol. 7, Issue 1.

Targeting the insulin-like growth factor axis

Targeting the insulin-like growth factor axis for the development of novel therapeutics in oncology. Gao J, Chang YS, Jallal B, Viner J. Cancer Res. 2012 72(1):3-12. Review.


Elected to the Board of Trustees, Johns Hopkins University, 2014


Recipient, Maryland’s International Business Leadership Award, 2014


Life Without Lupus Scientific Honoree, 2014